Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2018 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.77%

Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still rose by 0.77%, suggesting that investors may be optimistic about the company's long-term prospects despite the EPS miss. The lack of revenue figures and guidance may contribute to ongoing uncertainty.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.61	N/A	-6.41%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concern over the EPS miss but emphasized their commitment to long-term strategies. They did not provide specific revenue guidance.

Management acknowledged challenges in meeting EPS expectations.

No specific revenue figures were provided, indicating uncertainty.

The focus remains on long-term growth despite short-term setbacks.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.77%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.77%

Key numbers

Management commentary